Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases
Radium-223 dichloride (223Ra) (Sofigo), a calcium-mimetic agent that specifically targets bone lesions, was approved in 2020 by China Food and Drug Administration (CFDA) to treat castration‑resistant prostate cancer and bone metastases (CRPC) with symptomatic bone metastases and no known visceral me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Science Press
2021-12-01
|
| Series: | He jishu |
| Subjects: | |
| Online Access: | http://www.hjs.sinap.ac.cn/thesisDetails#10.11889/j.0253-3219.2021.hjs.44.120301&lang=zh |